alexa To Compare the Cost of Rituximab and DCP Therapy in Pem
ISSN: 2155-9554

Journal of Clinical & Experimental Dermatology Research
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

To Compare the Cost of Rituximab and DCP Therapy in Pemphigus in a Government Tertiary Hospital

Rohith Kanchan*, Sushruth Guruput Kamoji and Malteshgouda Ningappa Patil

Department of Dermatology, Belagavi Institute of Medical Sciences, India

*Corresponding Author:
Rohith Kanchan
Department of Dermatology
Belagavi Institute of Medical Sciences, India
Tel: +9611146061
E-mail: [email protected]

Received date: February 26, 2017; Accepted date: March 06, 2017; Published date: March 08, 2017

Citation: Kanchan R, Kamoji SG, Patil MN (2017) To Compare the Cost of Rituximab and DCP Therapy in Pemphigus in a Government Tertiary Hospital. J Clin Exp Dermatol Res 8:387. doi: 10.4172/2155-9554.1000387

Copyright: © 2017 Kanchan R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Background: Pulsed corticosteroids are the mainstay in management of pemphigus but long term use is associated with numerous side effects. Biologics have shown promising results with minimal adverse effects but are expensive.

Aim: To compare the cost of DCP & low-dose Rituximab therapy in pemphigus in a government tertiary hospital.

Methods: We calculated the cost of DCP therapy (3 phases) and low dose Rituximab therapy in the treatment of pemphigus. These were considered under direct (medicines, usables for administering the medicines) and indirect costs (hospitalization, travel, loss of pay, the need for one attender) and a comparison were drawn.

Results: The cost of DCP therapy for 3 phases over 27 months totalled up to 87,800 while the cost of Rituximab therapy over 1 month was 49,594. Low dose Rituximab therapy was clearly more cost effective.

Limitations: We have not compared the efficacy of drugs, adverse effect profile or quality of life of patients in DCP and Rituximab group. Usables and steroids are free for patients in government hospital which partially reduces the cost of DCP further.

Conclusion: Low dose Rituximab therapy has a high upfront cost but still proves to be very cost effective compared to DCP. Going by the published data on efficacy and safety of low dose Rituximab, it can provide better quality of life due to fast and sustained remission, drastically reduce the duration of hospital stay, reduced burden of the disease on the family and medical fraternity. It is time to switch to safer, cheaper and more effective remedies.

Key messages: If the safety and efficacy of Rituximab can be clearly established, then it should be considered as a first line therapy for pemphigus.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords